198 related articles for article (PubMed ID: 18156171)
21. Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.
Nozza A; Siracusano L; Armando S
Clin Ther; 2006 Jun; 28(6):953-9. PubMed ID: 16860177
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib in combination with dexamethasone for relapsed multiple myeloma.
Kropff MH; Bisping G; Wenning D; Volpert S; Tchinda J; Berdel WE; Kienast J
Leuk Res; 2005 May; 29(5):587-90. PubMed ID: 15755512
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Jagannath S; Barlogie B; Berenson JR; Singhal S; Alexanian R; Srkalovic G; Orlowski RZ; Richardson PG; Anderson J; Nix D; Esseltine DL; Anderson KC;
Cancer; 2005 Mar; 103(6):1195-200. PubMed ID: 15690325
[TBL] [Abstract][Full Text] [Related]
24. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment.
Heider U; Kaiser M; Müller C; Jakob C; Zavrski I; Schulz CO; Fleissner C; Hecht M; Sezer O
Eur J Haematol; 2006 Sep; 77(3):233-8. PubMed ID: 16923110
[TBL] [Abstract][Full Text] [Related]
26. Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
Dimopoulos MA; Anagnostopoulos A; Kyrtsonis MC; Castritis E; Bitsaktsis A; Pangalis GA
Haematologica; 2005 Dec; 90(12):1655-8. PubMed ID: 16330439
[TBL] [Abstract][Full Text] [Related]
27. The safety and efficacy of bortezomib in relapsed multiple myeloma.
Jagannath S
Clin Adv Hematol Oncol; 2006 May; 4(5):2-3; discussion 8; suppl 13. PubMed ID: 16830423
[No Abstract] [Full Text] [Related]
28. Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice.
Wu KL; van Wieringen W; Vellenga E; Zweegman S; Lokhorst HM; Sonneveld P
Haematologica; 2005 Jul; 90(7):996-7. PubMed ID: 15996946
[TBL] [Abstract][Full Text] [Related]
29. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.
Oakervee HE; Popat R; Curry N; Smith P; Morris C; Drake M; Agrawal S; Stec J; Schenkein D; Esseltine DL; Cavenagh JD
Br J Haematol; 2005 Jun; 129(6):755-62. PubMed ID: 15953001
[TBL] [Abstract][Full Text] [Related]
30. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.
Dubois D; Dhawan R; van de Velde H; Esseltine D; Gupta S; Viala M; de la Loge C
J Clin Oncol; 2006 Feb; 24(6):976-82. PubMed ID: 16432077
[TBL] [Abstract][Full Text] [Related]
31. [Bortezomib (Velcade) in relapsed/refractory multiple myeloma--the first experience in the Czech Republic].
Spicka I; Hájek R; Vytrasová M; Maisnar V; Gregora E; Schutzova M; Straub J; Scudla V; Adam Z; Klener P
Cas Lek Cesk; 2005; 144(9):636, 638-40. PubMed ID: 16193944
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.
Kröger N; Zabelina T; Ayuk F; Atanackovic D; Schieder H; Renges H; Zander A
Exp Hematol; 2006 Jun; 34(6):770-5. PubMed ID: 16728282
[TBL] [Abstract][Full Text] [Related]
33. Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
Musto P; Falcone A; Sanpaolo G; Guglielmelli T; Zambello R; Balleari E; Catalano L; Spriano M; Cavallo F; La Sala A; Mantuano S; Nobile M; Melillo L; Scalzulli PR; Dell'Olio M; Bodenizza C; Greco MM; Carella AM; Merla E; Carella AM; Boccadoro M; Cascavilla N; Palumbo A
Leuk Res; 2006 Mar; 30(3):283-5. PubMed ID: 16111749
[TBL] [Abstract][Full Text] [Related]
34. A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma.
Lee KW; Yun T; Song EK; Na II; Shin H; Bang SM; Lee JH; Lee ST; Kim JH; Yoon SS; Lee JS; Park S; Kim BK; Kim NK
J Korean Med Sci; 2005 Aug; 20(4):598-62. PubMed ID: 16100450
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients.
Badros AZ; Goloubeva O; Rapoport AP; Ratterree B; Gahres N; Meisenberg B; Takebe N; Heyman M; Zwiebel J; Streicher H; Gocke CD; Tomic D; Flaws JA; Zhang B; Fenton RG
J Clin Oncol; 2005 Jun; 23(18):4089-99. PubMed ID: 15867202
[TBL] [Abstract][Full Text] [Related]
36. A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.
Prince HM; Mileshkin L; Roberts A; Ganju V; Underhill C; Catalano J; Bell R; Seymour JF; Westerman D; Simmons PJ; Lillie K; Milner AD; Iulio JD; Zeldis JB; Ramsay R
Clin Cancer Res; 2005 Aug; 11(15):5504-14. PubMed ID: 16061867
[TBL] [Abstract][Full Text] [Related]
37. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
Jagannath S; Richardson PG; Barlogie B; Berenson JR; Singhal S; Irwin D; Srkalovic G; Schenkein DP; Esseltine DL; Anderson KC;
Haematologica; 2006 Jul; 91(7):929-34. PubMed ID: 16818280
[TBL] [Abstract][Full Text] [Related]
38. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
Maki RG; Kraft AS; Scheu K; Yamada J; Wadler S; Antonescu CR; Wright JJ; Schwartz GK
Cancer; 2005 Apr; 103(7):1431-8. PubMed ID: 15739208
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
Shah MH; Young D; Kindler HL; Webb I; Kleiber B; Wright J; Grever M
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6111-8. PubMed ID: 15447997
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib data show improved survival in patients with relapsed multiple myeloma.
Oncology (Williston Park); 2004 Aug; 18(9):1199, 1201. PubMed ID: 15471202
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
